- Smokers’ Immune Genetic Feature Found to Lower Lung Cancer Risk
- Study of 27 Million People: Cardiovascular Disease Patients May Be More Prone to Cancer
- Unlocking the Mystery of Fatigue: Acetylcholine Therapy for Post-COVID-19 Syndrome
- Study Finds Closing Toilet Lid Does Not Reduce Virus Spread
- The century-old BCG vaccine may be the nemesis of stubborn liver cancer
- New developments in kidney cancer treatment
Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine
- Japan: Over 10,000 Applications for Health Damage from COVID-19 Vaccines
- Antioxidant Supplementation May Accelerate Tumor Growth and Spread
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- ‘Elixir of Immortality’ Nicotinamide Riboside (NR) Virtually No Effect
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine.
VLP Therapeutics hired Fujifilm to help it manufacture COVID-19 vaccine candidates for clinical trials. According to the undisclosed financial terms of the transaction, Fujifilm needs to produce lipid nanoparticles for delivery of mRNA vaccines, and will participate in the process and formulation development, with the purpose of working hard to advance the vaccine to the clinical trial stage.
Mizuki Itou, a spokesperson for Fujifilm Holdings (the parent company of Fujifilm), told us: “This collaboration is under the responsibility of Fujifilm’s pharmaceutical department in Japan,” Itou explained, “We will use the PNI NanoAssembler series of technologies to make nanoparticles. , Production will be carried out at the facilities of Fujifilm Toyama Chemical Company in Toyama Prefecture, Japan.”
As early as March last year, Fujifilm partnered with Canada-based Precision Nano Systems (PNI) to reach an agreement focusing on adding nano-drug development and production capabilities to its products, thereby obtaining this technology.
Itou added, “Fujifilm Diosynth Biotechnology, our contract development and manufacturing organization (CDMO), did not participate in the project.”
VLP’s COVID-19 vaccine candidate is based on self-replicating RNA vector technology. The idea is to provide genes that can change the characteristics of macrophages or dendritic cells so that they can activate the immune system to destroy cancer cells.
Facts have proved that the vaccine induces virus-neutralizing antibodies within two weeks after vaccination. According to a report by NS-Healthcare, the VLP plans to conduct further animal research and clinical trials in Japan with the National Center for Global Health and Medical Sciences, the National Institute of Biomedical Innovation, Health and Nutrition, Oita University and Osaka City University.
According to an agreement negotiated in August 2020, the vaccine development project is also supported by the Japan Medical Research and Development Agency (AMED).
The commercial scale production plan of the vaccine is underway.
Itou told us: “So far, no decision has been made on commercial supply. As the project progresses, we will discuss with VLP Therapeutics.”
In June of this year, Danaher’s life science platform completed the acquisition of Precision NanoSystems (PNI). Headquartered in Vancouver, Canada, PNI is a global expert in the development of technologies and solutions for genetic medicine (including mRNA vaccines and therapeutic drugs).
PNI will join Danaher’s life science platform and complement its current businesses (including Cytiva and Pall).
Cytiva is a pioneer in the field of global life sciences, with 8,000 employees in more than 40 countries and regions around the world, committed to advancing unseen technologies and accelerating extraordinary treatments.
As a reliable partner for customers, Cytiva focuses on research in life sciences and biotechnology for the development of innovative vaccines, biopharmaceuticals, and new cell and gene therapies.
By improving the speed, efficiency and capabilities of drug development and biotechnology, the development and production of transformative drugs and therapies for the benefit of patients around the world. Please visit cytiva.com.cn for more information.
Fujifilm uses PNI technology to make nanoparticles for VLP’s COVID-19 vaccine
(source:internet, reference only)
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.